The Future of Lung Cancer Screening: Implementing, Expanding, and Innovating
All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.
Moderators
Chi-Fu Jeffrey Yang, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing); Genentech: Advisory Board (Ongoing)
Ammara A. Watkins, MD, MPH
Presentations
- Expanding Eligibility Criteria for Lung Cancer Screening: Pro
Douglas E. Wood, MD, FACS, FRCSEd
- Expanding Eligibility Criteria for Lung Cancer Screening: Con
Chris Slatore, MD, MS
- Discussion
- After Screening Surgical Follow Up
Cherie Erkmen, MD
Disclosure(s): AstraZeneca; BMS; Merck; Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer, USA: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
- Incidental Nodules vs. Screen-Detected Nodules: Is There a Difference?
Neel Chudgar, MD
Disclosure(s): AstraZeneca: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); LUNGevity: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
- Lung Cancer and Lung Cancer Screening in Individuals Without a Smoking History
Natalie Lui, MD
Disclosure(s): Centese: Sponsored research agreement (Terminated, June 30, 2024); Intuitive Foundation: Research grant (Terminated, June 30, 2024); Intuitive Surgical: Consultant (Ongoing)
- Discussion
- Reassessing Efficacy: Understanding Failures in Lung Cancer Screening Despite Low-Dose CT Protocol Adherence
Victoria Shiqi Wu
- The Harms of Lung Cancer Screening: Telling Truths and Dispelling Myths
Hari B. Keshava, MD MS FACS
Disclosure(s): AstraZeneca (Any division): Consultant (Ongoing), Speaker (Ongoing)
- Novel Adjuncts to Lung Cancer Screening to Expand Screening Eligibility and Reduce Screening Harms
Jane Yanagawa, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Steering Committee Member (Ongoing); OncLive: Lung Cancer Workshop Attendee (Ongoing)
- Discussion
- Achieving Equitable Care for Underrepresented Minority Patients with a Lung Cancer Screening Program
Azante Griffith
Available Credit
- 1.75 ABS Accredited CME
- 1.75 ABTS Accredited CME
- 1.75 AMA PRA Category 1 Credit™
Price
Cost:
$0.00
All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.
Moderators
Chi-Fu Jeffrey Yang, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing); Genentech: Advisory Board (Ongoing)
Ammara A. Watkins, MD, MPH
Presentations
- Expanding Eligibility Criteria for Lung Cancer Screening: Pro
Douglas E. Wood, MD, FACS, FRCSEd
- Expanding Eligibility Criteria for Lung Cancer Screening: Con
Chris Slatore, MD, MS
- Discussion
- After Screening Surgical Follow Up
Cherie Erkmen, MD
Disclosure(s): AstraZeneca; BMS; Merck; Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer, USA: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
- Incidental Nodules vs. Screen-Detected Nodules: Is There a Difference?
Neel Chudgar, MD
Disclosure(s): AstraZeneca: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); LUNGevity: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
- Lung Cancer and Lung Cancer Screening in Individuals Without a Smoking History
Natalie Lui, MD
Disclosure(s): Centese: Sponsored research agreement (Terminated, June 30, 2024); Intuitive Foundation: Research grant (Terminated, June 30, 2024); Intuitive Surgical: Consultant (Ongoing)
- Discussion
- Reassessing Efficacy: Understanding Failures in Lung Cancer Screening Despite Low-Dose CT Protocol Adherence
Victoria Shiqi Wu
- The Harms of Lung Cancer Screening: Telling Truths and Dispelling Myths
Hari B. Keshava, MD MS FACS
Disclosure(s): AstraZeneca (Any division): Consultant (Ongoing), Speaker (Ongoing)
- Novel Adjuncts to Lung Cancer Screening to Expand Screening Eligibility and Reduce Screening Harms
Jane Yanagawa, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Steering Committee Member (Ongoing); OncLive: Lung Cancer Workshop Attendee (Ongoing)
- Discussion
- Achieving Equitable Care for Underrepresented Minority Patients with a Lung Cancer Screening Program
Azante Griffith